Ophthalmic Drugs Market
Ophthalmic Drugs Market Study by Anti-inflammatory Drugs, Anti-infective Drugs, Anti-glaucoma Drugs, Anti-allergy Drugs, and Anti-VEGF Drugs from 2023 to 2033
Analysis of Ophthalmic Drugs Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Ophthalmic Drugs Market Outlook (2023 to 2033)
Global demand for ophthalmic drugs is predicted to increase at a CAGR of 6.6% from 2023 to 2033. The global ophthalmic drugs market is valued at US$ 38 billion in 2023 and is thus anticipated to reach US$ 72 billion by 2033-end.
The use of ophthalmic drugs for retinal disorders is anticipated increase at a CAGR of 5% during the forecast period due to the increasing patient pool acquiring retinal problems, the presence of innovative pipeline drugs, and increased financing for the development of retinal disorder treatments.
Ophthalmic drugs are prescribed for the treatment of a variety of eye-related conditions, such as age-related macular degeneration (AMD), cytomegalovirus (CMV), diabetic macular edema, color blindness, and diabetic macular edema. The conjunctiva SAC might be injected with a liquid drop preparation, an ointment, or a lotion to administer the medication. The right dosage and strength of the medication are chosen, and it is administered to the eyes in the prescribed manner.
The issue of low bioavailability of medicinal substances after application to the eyeball is the primary driver of scientists' pervasive interest in these medication forms. These drugs may be administered through contact lenses, emulsions, ointments, aqueous gels, dendrimers, or nanosuspensions. Neomycin, antibiotics, bacitracin, and polymyxin are all used in the production of ophthalmic medications, which help to slow the spread of bacterial infections in the eyes.
There is an increase in incidences of eye-related diseases, particularly in developing countries, over the past several years. Visual impairment is a global health concern harming physical and mental health. The increasing patient pool of the visually impaired is anticipated to boost demand for healthcare spending on ophthalmic drugs.
The ophthalmic drugs market is expected to rise as a result of several major factors, including a growing elderly population, an increase in the prevalence of eye ailments, technological advancements, and rising healthcare spending awareness. Market expansion is being supported by the substantial financing and supportive measures being implemented by the governments of numerous countries to stimulate the creation of efficient ophthalmic medications with novel formulations and combinations.
Additional growth-promoting elements include substantial technological developments, such as the development of gene-drug therapy for the diagnosis and treatment of hereditary ophthalmic, neurovascular retinal, and retinoblastoma problems.
Furthermore, the easy accessibility of ophthalmic medications in the forms of eye solutions, drops, capsules, pills, gels, and ointments via several online and offline distribution channels is fostering market expansion. A favorable outlook for the ophthalmic drugs market is being created by other factors such as the rapid expansion of the pharmaceutical industry and an increase in R&D operations to develop affordable ocular drug delivery systems (ODDS).
Report Attributes |
Details |
Ophthalmic Drugs Market Size (2023) |
US$ 38 Billion |
Projected Market Value (2033) |
US$ 72 Billion |
Global Market Growth Rate (2023 to 2033) |
6.6% CAGR |
Market Share of Anti-glaucoma Drugs |
60% |
Key Companies Profiled |
|
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Which Key Aspects are Shaping Ophthalmic Drug Demand across the World?
“Growing Usage of Contact Lenses and Rise in Geriatric Population”
Compared to the use of glasses, contact lens use has significantly increased in recent years. The use of contact lenses by individuals who experience dry eye conditions has led to a large rise in the need for ophthalmic medications.
Many people are suffering from age-related illnesses. The demand for pharmaceuticals used as preventative measures and for treating various ailments has increased recently, and this trend will continue during the projection period.
“Increase in Patients Suffering from Various Eye Disorders”
Demand for ophthalmic drugs is predicted to increase due to a rise in patients experiencing vision impairment. With the aid of various medications, it is possible to prevent these disorders, which will prove to be a significant opportunity for market expansion over the coming years. Surging diabetes incidence in the elderly population and the eye ailment known as diabetic retinopathy are the elements boosting sales of ophthalmic drugs.
“New Developments in Drug Delivery Techniques”
The ophthalmic drugs market is expected to increase as a result of rising research and development efforts to create and introduce novel ophthalmic medications, as well as several strategic initiatives by the major players. Ophthalmic drugs have a considerable competitive edge over their counterparts due to their multiyear drug delivery system. Implanted contact lenses and medicines are two other innovative medication delivery methods.
The development of gene therapies as an effective means of drug delivery is one of the major factors driving this industry. Gene therapy enables the modification of patient cells to produce particular therapeutic entities using viral or non-viral vectors in both in-vitro and in-vivo settings.
Gene therapy can be used to identify and treat retinoblastoma, neurovascular retinal abnormalities, and inherited ophthalmic illnesses such as retinitis pigmentosa. Over the projection period, there should be potential for market expansion as more research is needed to advance and widen the application of gene therapy across ophthalmic illnesses.
Growing awareness of advanced treatment options for a variety of eye disorders patients and medical professionals is driving the demand for novel ophthalmic drugs. Manufacturers are also concentrating on creating advanced drug delivery systems that can increase patient compliance rates and lessen negative effects related to conventional therapies.
What Obstacles Need to Be Tackled by Suppliers of Ophthalmic Drugs?
“Lack of Skilled Professionals and Adverse Effects of Ophthalmic Medications”
Market expansion is anticipated to be constrained by the loss of patent protection for popular medications used to treat eye illnesses and the absence of health insurance in developing countries. The high cost of product development is expected to restrain market growth over the coming years, according to pricing trends.
The market for ophthalmic drugs will be challenged by the shortage of skilled professionals and the adverse effects of ophthalmic medications may impede market revenue.
Which Region is Predicted to Lead Market Expansion Going Forward?
“Favorable Reimbursement Policies Driving Market Growth in North America”
North America accounts for 50% share of the global market owing to the rising prevalence of eye diseases. Growing initiatives by key market players to develop innovative drugs, favorable reimbursement policies, and growing awareness of early ophthalmic disease diagnosis are supporting market expansion in the region.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Which Country is Asserting its Dominance in North America?
“Growing Awareness among People about Accessibility of Ophthalmic Drugs”
The market is predicted to be dominated by the United States due to the increase in the prevalence of blindness, vision impairment, and other eye-related illnesses. Market growth in the United States is attributed to the growing awareness among people about the accessibility of ophthalmic drugs, increased government investments in eye health, and the availability of qualified healthcare professionals.
What is Benefitting Providers of Ophthalmic Drugs in Germany?
“Increase in Drug Approvals in the Country”
The main reason fueling the expansion of the market in Germany is improved regulatory policies, which have strengthened consumer confidence in the pharmaceutical industry. Key companie's strategic moves toward the commercialization of a few medicines, the presence of a large patient pool, increased drug approvals, and a rise in the local supply of ophthalmic drugs are boosting market value in Germany.
What is Making Japan Stand Out in the Asia Pacific Market?
“Increasing Investments by Research Institutes for Innovations in Ophthalmic Drugs”
The growing elderly population, higher healthcare spending, improved healthcare infrastructure, and a rise in consumer disposable income levels are the factors supporting market expansion in Japan. Increasing investments by research institutes for innovations in ophthalmic drugs are driving market growth in Japan.
Category-wise Insights
Why are Anti-glaucoma Drugs Highly Preferred?
“Rising Pool of Glaucoma Patients Driving Sales of Anti-glaucoma Drugs”
Based on therapeutic class, the market is classified into anti-inflammatory drugs, anti-infective drugs, anti-glaucoma drugs, anti-allergy drugs, anti-VEGF drugs, and others. Anti-glaucoma drugs account for 60% share of the global market.
Abnormally high pressure in the eye is generally the cause of glaucoma, a group of eye illnesses that impair the optic nerve, which is necessary for clear vision. A class of pharmaceuticals called anti-glaucoma ophthalmic drugs is used to reduce the pressure inside the eye. These drugs may be useful in lowering the risk of glaucoma, a disorder that can impair eyesight.
Rising geriatric population, which is more prone to developing glaucoma, and the increasing prevalence of glaucoma are the elements driving the demand for anti-glaucoma drugs. Key businesses are putting more emphasis on creating innovative medicines and products to treat glaucoma patients. This is anticipated to result in more product releases, which will fuel market expansion.
Which Product Accounts for a Leading Market Share?
“Prescription Drugs More Preferred Due to High Efficacy in Treating Ocular Conditions”
Based on product, the market is divided into prescription drugs and OTC drugs. Prescription drugs hold 50% share of the global market owing to an increase in conditions such as AMD and diabetic retinopathy. Improved safety and efficacy are two variables driving the demand for prescription drugs.
Some prescription drugs have lubricating and moisturizing ingredients that temporarily increase tear production. Prescription drugs are chosen over over-the-counter ones because they are thought to be the most effective in treating ocular conditions.
Additionally, a rising success rate for recently introduced prescription-only medicines would support market expansion. Since these medications are intended to be applied to the eyes only, patients must have a prescription before receiving ophthalmic steroids.
Competitive Landscape
Top ophthalmic drug manufacturers are focusing on supply chain management, collaborations with other companies, and enhancing quality control to gain a competitive edge in the market. Leading companies are improving product standards of new ophthalmic drugs and innovating their development formula following safety regulations to lower the environmental impact.
Major players are investing heavily in extensive R&D initiatives to increase their market share. Product portfolio expansion and mergers and acquisitions are two important techniques used by key participants.
For instance :
- Santen Pharmaceutical Co. and Singapore Eye Research Institute announced a strategic collaboration to develop new technologies for unmet medical needs in key ophthalmic drug domains. The company manufactures prescription drugs for corneal, retinal, and glaucoma diseases, which include Diquas, Tapros, Alesion, and Eylea. Novartis AG, another player, integrates new products into its existing pipeline of drugs. It specializes in innovative medicines and includes ophthalmic drug products such as Lucentis and Travoprost.
- In 2022, Novartis acquired Kedalion Therapeutics and its ground-breaking ocular delivery system, which can improve the patient experience.
Key Segments of Ophthalmic Drugs Industry Research
-
By Therapeutic Class :
- Anti-inflammatory Drugs
- NSAIDs
- Steroids
- Anti-infective Drugs
- Anti-fungal Drugs
- Anti-bacterial Drugs
- Others
- Anti-glaucoma Drugs
- Alpha Agonist
- Beta Blockers
- Prostaglandin Analogs
- Combined Medication
- Others
- Anti-allergy Drugs
- Anti-VEGF Drugs
- Others
- Anti-inflammatory Drugs
-
By Product :
- Prescription Drugs
- OTC Drugs
-
By Disease Indication :
- Dry Eye
- Glaucoma
- Infection/Inflammation
- Retinal Disorders
- Wet AMD
- Dry AMD
- Diabetic Retinopathy
- Others
- Allergy
- Uveitis
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Online Pharmacies
- Independent Pharmacies & Drug Stores
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Market 4. Market Overview 4.1. Introduction 4.1.1. Disease Indication Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Key Market Indicators 4.4. Market Dynamics 4.4.1. Drivers 4.4.2. Restraints 4.4.3. Opportunity 4.4.4. Trends 4.5. Global Market Analysis and Forecasts, 2023–2033 4.5.1. Market Revenue Projections (US$ Mn) 4.6. Porter’s Five Force Analysis 4.7. Market Outlook 4.8. Global Company Share Analysis: Glaucoma; 2018 4.9. Pipeline Analysis: Major Market Players 4.10. Pipeline Analysis: Emerging Market Players 4.11. Comparison matrix for product offerings: Major Market Players 4.12. Snapshot: Causes of blindness - Global 4.13. Snapshot: Causes of blindness - Regional 5. Global Market Analysis and Forecasts, By Disease Indication 5.1. Introduction & Definition 5.2. Key Findings / Developments 5.3. Key Trends 5.4. Market Value Forecast by Disease Indication, 2023–2033 5.4.1. Dry Eye 5.4.2. Glaucoma 5.4.3. Infection/Inflammation 5.4.4. Retinal Disorders 5.4.4.1. Wet AMD 5.4.4.2. Dry AMD 5.4.4.3. Diabetic Retinopathy 5.4.4.4. Others 5.4.5. Allergy 5.4.6. Uveitis 5.4.7. Others 5.5. Market Attractiveness by Disease Indication 6. Global Market Analysis and Forecasts, By Therapeutic Class 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Key Trends 6.4. Market Value Forecast By Therapeutic Class, 2023–2033 6.4.1. Anti-inflammatory Drugs 6.4.1.1. NSAID 6.4.1.2. Steroids 6.4.2. Anti-infective Drugs 6.4.2.1. Anti-fungal Drugs 6.4.2.2. Anti-bacterial Drugs 6.4.2.3. Others 6.4.3. Anti-glaucoma Drugs 6.4.3.1. Alpha Agonist 6.4.3.2. Beta Blockers 6.4.3.3. Prostaglandin Analogs 6.4.3.4. Combined Medication 6.4.3.5. Others 6.4.4. Anti-allergy Drugs 6.4.5. Anti-VEGF Agents 6.4.6. Others 6.5. Market Attractiveness by Therapeutic Class 7. Global Market Analysis and Forecasts, By Product Type 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Key Trends 7.4. Market Value Forecast by Product Type, 2023–2033 7.4.1. Prescription Drugs 7.4.2. OTC Drugs 7.5. Market Attractiveness by Product Type 8. Global Market Analysis and Forecasts, By Distribution Channels 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Key Trends 8.4. Market Value Forecast by Distribution Channels, 2023–2033 8.4.1. Hospital Pharmacies 8.4.2. Online Pharmacies 8.4.3. Independent Pharmacies & Drug Stores 8.5. Market Attractiveness by Distribution Channels 9. Global Market Analysis and Forecasts, By Region 9.1. Key Findings 9.2. Policies and Regulations 9.3. Market Value Forecast by Region 9.3.1. North America 9.3.2. Europe 9.3.3. Asia Pacific 9.3.4. Latin America 9.3.5. Middle East and Africa 9.4. Market Attractiveness by Country/Region 10. North America Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.1.2. Policies and Regulations 10.1.3. Key Trends 10.2. Market Value Forecast by Disease Indication, 2023–2033 10.2.1. Dry Eye 10.2.2. Glaucoma 10.2.3. Infection/Inflammation 10.2.4. Retinal Disorders 10.2.4.1. Wet AMD 10.2.4.2. Dry AMD 10.2.4.3. Diabetic Retinopathy 10.2.4.4. Others 10.2.5. Allergy 10.2.6. Uveitis 10.2.7. Others 10.3. Market Value Forecast by Therapeutic Class, 2023–2033 10.3.1. Anti-inflammatory Drugs 10.3.1.1. NSAID 10.3.1.2. Steroids 10.3.2. Anti-infective Drugs 10.3.2.1. Anti-fungal Drugs 10.3.2.2. Anti-bacterial Drugs 10.3.2.3. Others 10.3.3. Anti-glaucoma Drugs 10.3.3.1. Alpha Agonist 10.3.3.2. Beta Blockers 10.3.3.3. Prostaglandin Analogs 10.3.3.4. Combined Medication 10.3.3.5. Others 10.3.4. Anti-allergy Drugs 10.3.5. Anti-VEGF Agents 10.3.6. Others 10.4. Market Value Forecast by Product Type, 2023–2033 10.4.1. Prescription Drugs 10.4.2. OTC Drugs 10.5. Market Value Forecast by Distribution Channels, 2023–2033 10.5.1. Hospital Pharmacies 10.5.2. Online Pharmacies 10.5.3. Independent Pharmacies & Drug Stores 10.6. Market Value Forecast by Country, 2023–2033 10.6.1. U.S. 10.6.2. Canada 10.7. Market Attractiveness Analysis 10.7.1. By Disease Indication 10.7.2. By Therapeutic Class 10.7.3. By Product Type 10.7.4. By Distribution Channels 10.7.5. By Country 11. Europe Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.1.2. Policies and Regulations 11.1.3. Key Trends 11.2. Market Value Forecast by Disease Indication, 2023–2033 11.2.1. Dry Eye 11.2.2. Glaucoma 11.2.3. Infection/Inflammation 11.2.4. Retinal Disorders 11.2.4.1. Wet AMD 11.2.4.2. Dry AMD 11.2.4.3. Diabetic Retinopathy 11.2.4.4. Others 11.2.5. Allergy 11.2.6. Uveitis 11.2.7. Others 11.3. Market Value Forecast by Therapeutic Class, 2023–2033 11.3.1. Anti-inflammatory Drugs 11.3.1.1. NSAID 11.3.1.2. Steroids 11.3.2. Anti-infective Drugs 11.3.2.1. Anti-fungal Drugs 11.3.2.2. Anti-bacterial Drugs 11.3.2.3. Others 11.3.3. Anti-glaucoma Drugs 11.3.3.1. Alpha Agonist 11.3.3.2. Beta Blockers 11.3.3.3. Prostaglandin Analogs 11.3.3.4. Combined Medication 11.3.3.5. Others 11.3.4. Anti-allergy Drugs 11.3.5. Anti-VEGF Agents 11.3.6. Others 11.4. Market Value Forecast by Product Type, 2023–2033 11.4.1. Prescription Drugs 11.4.2. OTC Drugs 11.5. Market Value Forecast by Distribution Channels, 2023–2033 11.5.1. Hospital Pharmacies 11.5.2. Online Pharmacies 11.5.3. Independent Pharmacies & Drug Stores 11.6. Market Value Forecast by Country, 2023–2033 11.6.1. U.K. 11.6.2. Germany 11.6.3. France 11.6.4. Italy 11.6.5. Spain 11.6.6. Russia 11.6.7. Rest of Europe 11.7. Market Attractiveness Analysis 11.7.1. By Disease Indication 11.7.2. By Therapeutic Class 11.7.3. By Product Type 11.7.4. By Distribution Channels 11.7.5. By Country 12. Asia Pacific Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.1.2. Policies and Regulations 12.1.3. Key Trends 12.2. Market Value Forecast by Disease Indication, 2023–2033 12.2.1. Dry Eye 12.2.2. Glaucoma 12.2.3. Infection/Inflammation 12.2.4. Retinal Disorders 12.2.4.1. Wet AMD 12.2.4.2. Dry AMD 12.2.4.3. Diabetic Retinopathy 12.2.4.4. Others 12.2.5. Allergy 12.2.6. Uveitis 12.2.7. Others 12.3. Market Value Forecast by Therapeutic Class, 2023–2033 12.3.1. Anti-inflammatory Drugs 12.3.1.1. NSAID 12.3.1.2. Steroids 12.3.2. Anti-infective Drugs 12.3.2.1. Anti-fungal Drugs 12.3.2.2. Anti-bacterial Drugs 12.3.2.3. Others 12.3.3. Anti-glaucoma Drugs 12.3.3.1. Alpha Agonist 12.3.3.2. Beta Blockers 12.3.3.3. Prostaglandin Analogs 12.3.3.4. Combined Medication 12.3.3.5. Others 12.3.4. Anti-allergy Drugs 12.3.5. Anti-VEGF Agents 12.3.6. Others 12.4. Market Value Forecast by Product Type, 2023–2033 12.4.1. Prescription Drugs 12.4.2. OTC Drugs 12.5. Market Value Forecast by Distribution Channels, 2023–2033 12.5.1. Hospital Pharmacies 12.5.2. Online Pharmacies 12.5.3. Independent Pharmacies & Drug Stores 12.6. Market Value Forecast by Country, 2023–2033 12.6.1. India 12.6.2. China 12.6.3. Japan 12.6.4. Australia & New Zealand 12.6.5. Rest of Asia Pacific 12.7. Market Attractiveness Analysis 12.7.1. By Disease Indication 12.7.2. By Therapeutic Class 12.7.3. By Product Type 12.7.4. By Distribution Channels 12.7.5. By Country 13. Latin America Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.1.2. Policies and Regulations 13.1.3. Key Trends 13.2. Market Value Forecast by Disease Indication, 2023–2033 13.2.1. Dry Eye 13.2.2. Glaucoma 13.2.3. Infection/Inflammation 13.2.4. Retinal Disorders 13.2.4.1. Wet AMD 13.2.4.2. Dry AMD 13.2.4.3. Diabetic Retinopathy 13.2.4.4. Others 13.2.5. Allergy 13.2.6. Uveitis 13.2.7. Others 13.3. Market Value Forecast by Therapeutic Class, 2023–2033 13.3.1. Anti-inflammatory Drugs 13.3.1.1. NSAID 13.3.1.2. Steroids 13.3.2. Anti-infective Drugs 13.3.2.1. Anti-fungal Drugs 13.3.2.2. Anti-bacterial Drugs 13.3.2.3. Others 13.3.3. Anti-glaucoma Drugs 13.3.3.1. Alpha Agonist 13.3.3.2. Beta Blockers 13.3.3.3. Prostaglandin Analogs 13.3.3.4. Combined Medication 13.3.3.5. Others 13.3.4. Anti-allergy Drugs 13.3.5. Anti-VEGF Agents 13.3.6. Others 13.4. Market Value Forecast by Product Type, 2023–2033 13.4.1. Prescription Drugs 13.4.2. OTC Drugs 13.5. Market Value Forecast by Distribution Channels, 2023–2033 13.5.1. Hospital Pharmacies 13.5.2. Online Pharmacies 13.5.3. Independent Pharmacies & Drug Stores 13.6. Market Value Forecast by Country, 2023–2033 13.6.1. Brazil 13.6.2. Mexico 13.6.3. Rest of Latin America 13.7. Market Attractiveness Analysis 13.7.1. By Disease Indication 13.7.2. By Therapeutic Class 13.7.3. By Product Type 13.7.4. By Distribution Channels 13.7.5. By Country 14. Middle East and Africa Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.1.2. Policies and Regulations 14.1.3. Key Trends 14.2. Market Value Forecast by Disease Indication, 2023–2033 14.2.1. Dry Eye 14.2.2. Glaucoma 14.2.3. Infection/Inflammation 14.2.4. Retinal Disorders 14.2.4.1. Wet AMD 14.2.4.2. Dry AMD 14.2.4.3. Diabetic Retinopathy 14.2.4.4. Others 14.2.5. Allergy 14.2.6. Uveitis 14.2.7. Others 14.3. Market Value Forecast by Therapeutic Class, 2023–2033 14.3.1. Anti-inflammatory Drugs 14.3.1.1. NSAID 14.3.1.2. Steroids 14.3.2. Anti-infective Drugs 14.3.2.1. Anti-fungal Drugs 14.3.2.2. Anti-bacterial Drugs 14.3.2.3. Others 14.3.3. Anti-glaucoma Drugs 14.3.3.1. Alpha Agonist 14.3.3.2. Beta Blockers 14.3.3.3. Prostaglandin Analogs 14.3.3.4. Combined Medication 14.3.3.5. Others 14.3.4. Anti-allergy Drugs 14.3.5. Anti-VEGF Agents 14.3.6. Others 14.4. Market Value Forecast by Product Type, 2023–2033 14.4.1. Prescription Drugs 14.4.2. OTC Drugs 14.5. Market Value Forecast by Distribution Channels, 2023–2033 14.5.1. Hospital Pharmacies 14.5.2. Online Pharmacies 14.5.3. Independent Pharmacies & Drug Stores 14.6. Market Value Forecast by Country, 2023–2033 14.6.1. South Africa 14.6.2. GCC Countries 14.6.3. Rest of Middle East and Africa 14.7. Market Attractiveness Analysis 14.7.1. By Disease Indication 14.7.2. By Therapeutic Class 14.7.3. By Product Type 14.7.4. By Distribution Channels 14.7.5. By Country 15. Competition Landscape 15.1. Market Player – Competition Matrix (By Tier and Size of companies) 15.2. Market Share Analysis by Company (2018) 15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy) 15.3.1. Aerie Pharmaceuticals, Inc. 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. SWOT Analysis 15.3.1.5. Strategic Overview 15.3.2. ALLERGAN 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.2.2. Financial Overview 15.3.2.3. Product Portfolio 15.3.2.4. SWOT Analysis 15.3.2.5. Strategic Overview 15.3.3. Valeant Pharmaceuticals International, Inc. 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.3.2. Financial Overview 15.3.3.3. Product Portfolio 15.3.3.4. SWOT Analysis 15.3.3.5. Strategic Overview 15.3.4. Bayer AG 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.4.2. Financial Overview 15.3.4.3. Product Portfolio 15.3.4.4. SWOT Analysis 15.3.4.5. Strategic Overview 15.3.5. Genentech, Inc. (F. Hoffmann-La Roche Ltd.) 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.5.2. Financial Overview 15.3.5.3. Product Portfolio 15.3.5.4. SWOT Analysis 15.3.5.5. Strategic Overview 15.3.6. Novartis AG 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.6.2. Financial Overview 15.3.6.3. Product Portfolio 15.3.6.4. SWOT Analysis 15.3.6.5. Strategic Overview 15.3.7. Pfizer Inc. 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.7.2. Financial Overview 15.3.7.3. Product Portfolio 15.3.7.4. SWOT Analysis 15.3.7.5. Strategic Overview 15.3.8. Regeneron Pharmaceuticals, Inc. 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.8.2. Financial Overview 15.3.8.3. Product Portfolio 15.3.8.4. SWOT Analysis 15.3.8.5. Strategic Overview 15.3.9. Santen Pharmaceutical Co., Ltd. 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.9.2. Financial Overview 15.3.9.3. Product Portfolio 15.3.9.4. SWOT Analysis 15.3.9.5. Strategic Overview 15.3.10. Shire 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strengths) 15.3.10.2. Financial Overview 15.3.10.3. Product Portfolio 15.3.10.4. SWOT Analysis 15.3.10.5. Strategic Overview 15.3.10.6. Others
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Product Offering - Major Market Players
Table 02: Global Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033
Table 03: Global Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023–2033
Table 04: Global Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033
Table 05: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023–2033
Table 06: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023–2033
Table 07: Global Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023–2033
Table 08: Global Market Size (US$ Mn) Forecast, by Product Type, 2023–2033
Table 09: Global Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 10: Global Market Size (US$ Mn) Forecast, by Region, 2023–2033
Table 11: North America Market Size (US$ Mn) Forecast, by Country, 2023–2033
Table 12: North America Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033
Table 13: North America Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023–2033
Table 14: North America Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033
Table 15: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023–2033
Table 16: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023–2033
Table 17: North America Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023–2033
Table 18: North America Market Size (US$ Mn) Forecast, by Product Type, 2023–2033
Table 19: North America Market Size (US$ Mn) Forecast, by Distribution Channels, 2023–2033
Table 20: Europe Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2023–2033
Table 21: Europe Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033
Table 22: Europe Market Size (US$ Mn) Forecast, Market Forecast, by Disease Indication – Retinal Disorder, 2023–2033
Table 23: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033
Table 24: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2023–2033
Table 25: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2023–2033
Table 26: Europe Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2023–2033
Table 27: Europe Market Size (US$ Mn) Forecast, by Product Type, 2023–2033
Table 28: Europe Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 29: Asia Pacific Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 30: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033
Table 31: Asia Pacific Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2023–2033
Table 32: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033
Table 33: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2023–2033
Table 34: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2023–2033
Table 35: Asia Pacific Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2023–2033
Table 36: Asia Pacific Market Size (US$ Mn) Forecast, by Product Type, 2023–2033
Table 37: Asia Pacific Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 38: Latin America Market Size (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 39: Latin America Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033
Table 40: Latin America Market Size (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2023–2033
Table 41: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033
Table 42: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2023–2033
Table 43: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2023–2033
Table 44: Latin America Market Size (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2023–2033
Table 45: Latin America Market Size (US$ Mn) Forecast, by Product Type, 2023–2033
Table 46: Latin America Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033
Table 47: Middle East & Africa Market Size (US$ Mn) Forecast, by Country/Sub-Region, 2023–2033
Table 48: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Indication, 2023–2033
Table 49: Middle East & Africa Market Size (US$ Mn) Forecast, by Disease Indication - Retinal Disorder, 2023–2033
Table 50: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class, 2023–2033
Table 51: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2023–2033
Table 52: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2023–2033
Table 53: Middle East & Africa Market Size (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2023–2033
Table 54: Middle East & Africa Market Size (US$ Mn) Forecast, by Product Type, 2023–2033
Table 55: Middle East & Africa Market Size (US$ Mn) Forecast, by Distribution Channel, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Size (US$ Mn) Forecast, 2023–2033
Figure 02: Global Company Share: Anti-glaucoma Drugs, 2018
Figure 03: Global Causes of Blindness
Figure 04: U.S. - Causes of Blindness
Figure 05: Europe - Causes of Blindness
Figure 06: Japan Causes of Blindness
Figure 07: Global Market Attractiveness, by Disease Indication, 2023–2033
Figure 08: Global Market Value Share, by Disease Indication, 2023 and 2033
Figure 09: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2023–2033
Figure 10: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2023–2033
Figure 11: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2023–2033
Figure 12: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2023–2033
Figure 13: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2023–2033
Figure 14: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2023–2033
Figure 15: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2023–2033
Figure 16: Global Market Attractiveness, by Therapeutic Class, 2023–2033
Figure 17: Global Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 19: Global Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033
Figure 18: Global Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033
Figure 20: Global Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033
Figure 21: Global Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033
Figure 22: Global Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033
Figure 23: Global Market, by Others Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2023–2033
Figure 24: Global Market Value Share, by Product Type, for 2023 and 2033
Figure 25: Global Market Attractiveness, by Product Type, 2023–2033
Figure 26: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2023–2033
Figure 27: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2023–2033
Figure 28: Global Market Value Share, by Distribution Channel, for 2023 and 2033
Figure 29: Global Market Attractiveness, by Distribution Channel, 2023–2033
Figure 30: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2023–2033
Figure 31: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2023–2033
Figure 32: Global Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2023–2033
Figure 33: Global Market Value Share, by Region, for 2023 and 2033
Figure 34: Global Market Attractiveness, by Region, 2023–2033
Figure 35: North America Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 36: North America Market Attractiveness, by Country, 2023–2033
Figure 37: North America Market Value Share, by Country, 2023 and 2033
Figure 38: North America Market Attractiveness, By Disease Indication, 2023–2033
Figure 39: North America Market Value Share, by Disease Indication, 2023 and 2033
Figure 40: North America Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 41: North America Market Attractiveness, by Therapeutic Class, 2023–2033
Figure 42: North America Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 43: North America Market Attractiveness, by Product Type, 2023–2033
Figure 44: North America Market Value Share, by Distribution Channels, 2023 and 2033
Figure 45: North America Market Attractiveness, by Distribution Channels, 2023–2033
Figure 46: Europe Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 47: Europe Market Attractiveness, by Country/Sub-Region, 2023–2033
Figure 48: Europe Market Value Share, by Country/Sub-Region, 2023 and 2033
Figure 49: Europe Market Attractiveness, By Disease Indication, 2015-2025
Figure 50: Europe Market Value Share, by Disease Indication, 2023 and 2033
Figure 51: Europe Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 52: Europe Market Attractiveness, by Therapeutic Class, 2023–2033
Figure 53: Europe Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 54: Europe Market Attractiveness, by Product Type, 2023–2033
Figure 55: Europe Market Value Share, by Distribution Channel, 2023 and 2033
Figure 56: Europe Market Attractiveness, by Distribution Channel, 2023–2033
Figure 57: Asia Pacific Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033
Figure 58: Asia Pacific Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 59: Asia Pacific Market Value Share, by Country/Sub-region, for 2023 and 2033
Figure 60: Asia Pacific Market Attractiveness, by Disease Indication, 2023–2033
Figure 61: Asia Pacific Market Value Share, by Disease Indication, for 2023 and 2033
Figure 62: Asia Pacific Market Attractiveness, by Therapeutic Class, 2023–2033
Figure 63: Asia Pacific Market Value Share, by Therapeutic Class, for 2023 and 2033
Figure 64: Asia Pacific Market Value Share Analysis, by Product Type, for 2023 and 2033
Figure 65: Asia Pacific Market Attractiveness, by Product Type, 2023–2033
Figure 66: Asia Pacific Market Value Share, by Distribution Channel, for 2023 and 2033
Figure 67: Asia Pacific Market Attractiveness, by Distribution Channel, 2023–2033
Figure 68: Latin America Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 69: Latin America Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 70: Latin America Market Value Share, by Country/Sub-region, 2023 and 2033
Figure 71: Latin America Market Attractiveness, by Disease Indication, 2023–2033
Figure 72: Latin America Market Value Share, by Disease Indication, 2023 and 2033
Figure 73: Latin America Market Attractiveness, by Therapeutic Class, 2023–2033
Figure 74: Latin America Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 75: Latin America Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 76: Latin America Market Attractiveness, by Product Type, 2023–2033
Figure 77: Latin America Market Value Share, by Distribution Channel, 2023 and 2033
Figure 78: Latin America Market Attractiveness, by Distribution Channel, 2023–2033
Figure 79: Middle East & Africa Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2023–2033
Figure 80: Middle East & Africa Market Attractiveness, by Country/Sub-Region, 2023–2033
Figure 81: Middle East & Africa Market Value Share, by Country/Sub-Region, 2023 and 2033
Figure 82: Middle East & Africa Market Attractiveness, by Disease Indication, 2023–2033
Figure 83: Middle East & Africa Market Value Share, by Disease Indication, 2023 and 2033
Figure 84: Middle East & Africa Market Attractiveness, by Therapeutic Class, 2023–2033
Figure 85: Middle East & Africa Market Value Share, by Therapeutic Class, 2023 and 2033
Figure 86: Middle East & Africa Market Value Share Analysis, by Product Type, 2023 and 2033
Figure 87: Middle East & Africa Market Attractiveness, by Product Type, 2023–2033
Figure 88: Middle East & Africa Market Value Share, by Distribution Channel, 2023 and 2033
Figure 89: Middle East & Africa Market Attractiveness, by Distribution Channel, 2023–2033
Figure 90: Global Market Share, by Company, 2018
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the value of the ophthalmic drugs market in 2023?
The global ophthalmic drugs market is valued at US$ 38 billion in 2023.
Which is the dominant regional market for ophthalmic drugs?
North America accounts for 50% share of the global market.
What is boosting the sales of ophthalmic drugs?
Increasing prevalence of eye diseases and growing geriatric population are driving market growth.
How big will the market for ophthalmic drugs be by 2033?
By 2033-end, the ophthalmic drugs market is expected to reach US$ 72 billion.
At what rate will ophthalmic drug demand evolve over the next ten years?
Worldwide consumption of ophthalmic drugs is estimated to rise at a CAGR of 6.6% through 2033.